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rug-Eluting Stenting
he Case for Post-Dilation
nrico Romagnoli, MD, PHD,* Giuseppe M. Sangiorgi, MD,* John Cosgrave, MD,*
douard Guillet,† Antonio Colombo, MD*
ilan, Italy; and Tolochenaz, Switzerland
n clinical practice, adequate stent deployment has an important effect on immediate and long-term
esults after percutaneous coronary interventions. In particular, suboptimal or incomplete stent expan-
ion is associated with increased restenosis and target vessel revascularization rates and, especially
ith drug-eluting stents (DES), might also predispose to stent thrombosis. Notwithstanding the signiﬁ-
ant improvement in technique and materials in the last decade, adjunctive high-pressure balloon dila-
ion is still necessary to improve the minimum stent area and the uniform volumetric stent expansion
n a majority of the cases. Indeed, in the published reports, the incidence of incomplete stent deploy-
ent ranges from 20% to 30% of cases, but it is signiﬁcantly higher in trials in which stent expansion
as assessed by intravascular ultrasound. Although there are not enough randomized studies about
his topic, data from published reports continue to support the use of proper post-dilation in the ma-
ority of patients undergoing both bare-metal stent and DES implantation. This review will summarize
he different anatomical, clinical, and device-related variables for increased risk of suboptimal stent de-
ivery, highlighting the importance of adequate high-pressure post-dilation to obtain optimal stent ex-
ansion to positively affect stent thrombosis and restenosis. (J Am Coll Cardiol Intv 2008;1:22–31)
2008 by the American College of Cardiology Foundationd
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sptimization of stent deployment during percuta-
eous coronary intervention (PCI) is a key element
o obtain most favorable immediate and long-term
esults. Since the introduction of balloon-expandable
are-metal stents (BMS) in common practice, the
eed was recognized for adequate stent expansion
o avoid suboptimal stent deployment and reduce
he incidence of target vessel revascularization
TVR) (1,2).
See page 32
Early-generation stents were delivered with a
ompliant balloon and systematically required fur-
her post-dilation with a noncompliant balloon at
igher pressures to obtain an adequate lumen
rom the *Emo Centro Cuore Columbus, Milan, Italy; and the
Medtronic Corporation, Tolochenaz, Switzerland.s
anuscript received July 23, 2007; revised manuscript received October
6, 2007, accepted October 25, 2007.ilation and complete apposition of stent struts to
he vessel wall (3–6). Notwithstanding the succes-
ive introduction of stent delivery systems based on
semi-compliant balloon allowing stent deploy-
ent at higher pressures (14 atm), post-dilation
ith a noncompliant balloon or using a larger
alloon is still demanded to attain the principle
media to media” stent expansion (7–12).
After the introduction of drug-eluting stents
DES) that dramatically improved restenosis and
VR, the importance of optimal stent deployment
as initially underestimated, leading to less use of
alloon post-dilation. In the major randomized clin-
cal trials (RCTs) testing DES, post-dilation was not
outinely performed (13–15). Nevertheless, despite
he lack of evidence from RCTs, observational data
ontinue to support the use of adjunctive balloon
ost-dilation after deployment of DES in the great
ajority of patients (16–21). Indeed, the current
tent delivery systems of DES are similar to if not the
ame as in BMS, and the risk of suboptimal stent
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23xpansion is still high. Importantly, suboptimal or incomplete
tent expansion, especially with DES with polymeric coating,
ot only might be associated with increased restenosis and
VR, but also might predispose to stent thrombosis (21–25).
The aim of this paper is to review all the possible causes
nd consequences of a suboptimal stent expansion and
ssess the possible role of adequate high-pressure balloon
ost-dilation to prevent it in the DES era.
iagnosis and Magnitude of
uboptimal Stent Deployment:
ole of Intravascular Ultrasound (IVUS)
ecause stent underexpansion is poorly recognized by an-
iography, the real incidence of suboptimal stent deploy-
ent is likely to be underestimated. Indeed, it has been
bserved that discrepancies exist between angiographically-
efined and IVUS-defined optimal stent deployment re-
ardless of the stent implanted, with the IVUS success rate
aging from 13% to 70% despite successful angiographic
esults (1,18,26–28). A comparison example between an-
iographic and IVUS results before and after high-pressure
tent post-dilation is shown in Figure 1.
An IVUS analysis is more accurate than angiography in
etermining in-stent dimension and is able to better detect
ubtle findings such as incomplete apposition and dissection
t the stent edges (29–33). Several trials in which stent
xpansion was assessed by IVUS, such as the STRUT (Stent
reatment Region assessed by Ultrasound Tomography)
34), CRUISE (Can Routine Ultrasound Influence Stent
xpansion) (7), and AVID (Angiography Versus Intravas-
ular Ultrasound Directed Coronary Stent Placement) (35)
tudies, showed an incidence of post-procedural incomplete
MS deployment raging from 4% to 22% (36). Similarly, a
igh rate of inadequate expansion, ranging between 24%
nd 28%, has also been observed with current DES (18).
Moreover, IVUS measurements have provided power-
ul predictive information regarding stent thrombosis,
estenosis, and TVR. In particular, minimal stent area
MSA) and minimal stent diameter (MSD) measured by
VUS at the end of the procedure are the strongest
redictors of TVR after BMS implantation in numerous
tudies (37– 41). Therefore, IVUS should be considered
he gold standard to verify the final result of a PCI
rocedure and should be recommended in those situa-
ions with increased risk of suboptimal stent deployment.
nfortunately this statement, even if it seems reasonable,
s so far supported only by “personal opinion” (Level of
vidence C).
One of the main problems in this field is the lack of a
niform and accepted definition of optimal stent expansion
y IVUS. Whereas angiographic optimal stent expansion Ian be qualified as 0% residual stenosis, such a clear
efinition is not present in the IVUS published data.
The first study that prospectively evaluated the effect of
ptimal stent expansion according to specific IVUS defini-
ions was the MUSIC (Multicenter Ultrasound Stenting in
oronaries) study (2). Table 1 shows the IVUS criteria
ntroduced in the MUSIC study to define “optimal” stent
xpansion. Subsequently, other studies assessing the role of
VUS-guided stent delivery adopted slightly different crite-
ia, which are summarized in Table 2.
In our view, the main limitation present in all criteria
roposed is that none of them takes the advantage given by
ositive remodeling at the lesion site. The presence of
ositive remodeling at the lesion site allows the dilation of
he stent to a size larger than the distal lumen. This
dvantage is particularly important when using long stents,
here it is useful to size each segment as close as possible to the
eal dimensions of the vessel and
ot just to an extrapolated target
aken from 2 references (proximal
nd distal) that are very far from
ach other. In such circum-
tances, criteria using an aver-
ge between the lumen proxi-
al and distal to the stent,
uch as in the TULIP (Throm-
ocyte activity evaluation and
ffects of Ultrasound guidance in
ong Intracoronary stent Place-
ent) study (8), becomes of lim-
ted value, owing to the discrep-
ncies between proximal and
istal lumen sizes. The closer we
re to the proximal or distal end
f a long stent, the larger will be
he inappropriate value of this
arget criterion.
The recently launched AVIO (Angiography Versus
VUS Optimisation) study, which has been designed to
ompare the long-term results with DES with an IVUS-
uided strategy versus an angiographic strategy, will use a
ovel criteria (i.e., a minimal luminal area 70% the
ominal balloon cross-sectional area [CSA] used to dilate a
pecific segment of the stent) to define optimal stent
mplantation. In addition, in this study, post-dilation non-
ompliant balloon size will be selected according to the
verage (maximum and minimum diameter) of the media to
edia diameter at the following points: distal in-stent
egment, proximal in-stent segment, and point in-stent of
aximal narrowing. Alternatively a lumen CSA 9 mm2
ill be considered adequate. In our opinion, these new
efinitions will overcome the limitations used in previous
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CSA  cross-sectional area
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasound
MSA  minimal stent area
MSD  minimal stent
diameter
PCI  percutaneous
coronary intervention
RCT  randomized clinical
trial
SES  sirolimus-eluting
stent(s)
TVR  target vessel
revascularizationVUS-guided RCTs.
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24eterminants of Suboptimal Stent Deployment
tent undersizing. Among the possible reasons for subop-
imal stent deployment, the first is certainly the undersizing
f the stent delivery balloon related to the target vessel.
Figure 1. Comparison of Angiographic and IVUS Findings Before and After
Comparison of angiographic and intravascular ultrasound (IVUS) results after h
loon of the same size (B). Note that by angiography, no clear difference can b
cant increase in lumen cross-sectional area (CSA) after a noncompliant balloon
Table 1. Optimal Stent Expansion Criteria Adopted in the MUSIC Study
IVUS Criteria Deﬁning Optimal Stent Deployment
1 Complete apposition of the stent over its entire length against the vessel
wall.
2A In case the in-stent luminal area 9.0 mm2:
● In-stent minimal lumen area 90% of the average reference lumen area
or 100% of lumen area of the reference segment with the lowest lumen
area;
● In-stent lumen area of proximal stent entrance 90% of proximal
reference lumen area.
2B In case the in-stent luminal area 9.0 mm2:
● In-stent minimal lumen area 80% of the average reference lumen area
or 90% of lumen area of the reference segment with the lowest lumen
area;
● In-stent lumen area of proximal stent entrance 90% of proximal
reference lumen area.
3 Symmetric stent expansion deﬁned by LDmin/LDmax 0.7.
IVUS intravascular ultrasound; LDmaxmaximum lumendiameter; LDminminimum lumenddiameter; MUSICMulticenter Ultrasound Stenting in Coronaries.ndeed, in patients with severe and diffuse target vessel
isease, the choice of the correct stent size on the basis of
nly angiographic evaluation is often difficult and leads very
ften to a balloon to artery ratio 1 (42,43). Our group
learly demonstrated that assessment of the reference vessel
iameter in coronary arteries significantly varies according
o the method of measurement used; a difference between
VUS and angiography1.0 mm was found in 71% of cases
ith vessel size 2.75 mm and in 49% of cases in patients
ith vessel size 2.75 mm, respectively (42).
Similarly, the recent practice of direct stenting might
ncrease the risk of stent undersizing, especially when
andled by nonexperienced operators and when used to
reat severe stenotic lesions preventing the correct estima-
ion of the distal vessel size.
It is worth noting that in case of undersizing of the stent
elivery balloon, high-pressure stent deployment, especially
ith the current semi-compliant balloon, can compensate
or the balloon undersizing only in part.
alloon device compliance and pressure deployment. An-
ther possible cause of stent underexpansion is strictly
elated to the compliance of balloons commonly used in
ressure Stent Post-Dilation
essure stent deployment (A) and after post-dilation with a noncompliant bal-
before and after the post-dilation. Conversely IVUS demonstrates a signiﬁ-
dilation.High-P
igh-pr
e seenelivery systems that are often not adequate to guarantee full
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25tent expansion at nominal pressures (26). Stent manufac-
urers provide a compliance chart relating balloon deploy-
ent pressure and the stent diameter. Nevertheless, com-
liance charts are based on in vitro measurement (in air or
n water), exclusively depending on material properties or
esign features of the stents themselves (44), but in vivo
tent expansion is mainly limited by lesion and vessel
ompliance. Several IVUS studies found that the real MSD
fter stent deployment was 20% to 26% less than the
nconstrained stent size displayed in the compliance chart
n the stent box (9,10,18,20,26,45). These differences were
ndependent of stent manufacturer, length, diameter, and
eployment pressure and related to the inherent resistance
f dilating a stent within an atherosclerotic artery (26,28).
Notwithstanding these discrepancies, the manufacturers’
ompliance charts are routinely used by interventional car-
iologists to optimize stent diameter according to inflation
ressure during PCI. Thus, in clinical practice, the pressure
Table 2. Optimal Stent Expansion Criteria Adopted in the Studies Assessin
Study (Ref. #)
Study
Design Primary End Point
Effect of
IVUS-Guided
Post-Dilation
on Primary
End Point
Albiero et al. (4) Case-control
study
Dichotomous angiographic
restenosis (50% stenosis)
NS
RESIST (68) Multicenter
randomized
6-month angiographic
restenosis (50% stenosis)
NS
AVID (35) Multicenter
randomized
Cumulative rate of death,
MI, or coronary artery
bypass graft surgery
NS
CRUISE (7) Case-control
study
Post-procedural MLD by
QCA and IVUS
Positive
SIPS (70) Multicenter
randomized
6-month angiographic
MLD
NS
OPTICUS (69) Multicenter
randomized
6-month angiographic
restenosis (50% DS),
MLD, and %DS
NS
TULIP (8) Multicenter
randomized
6-month MLD and MACE
(death/MI/TLR)
Positive
PRESTO
IVUS substudy (71)
Multicenter
randomized
9-month MACE (death/MI/
ischemia-driven TVR)
NS
AVID Angiography Versus Intravascular ultrasound Direct stent implantation; CRUISE Can Rou
major adverse cardiac events; MImyocardial infarction; MLAminimal lumen area; MLDmin
Optimization with ICUS to reduce stent restenosis; PRESTO  Prevention of Restenosis with Tranil
Stenting; SIPS Strategy for Intracoronary ultrasound-guided PTCA and Stenting; TLR target lesi
Intracoronary stent Placement; TVR  target vessel revascularization; other abbreviations as in Tabevel at which the stent is deployed probably represents the lritical determinant of final stent expansion and apposition
o the vessel wall. The importance of this issue has not
hanged with the new stent delivery systems based on
emi-compliant balloons, and DES showed the same prop-
rties as the corresponding BMS platforms (46). Therefore,
igh-pressure stent deployment is still strongly recom-
ended to obtain full expansion of both BMS and DES. In
his context, IVUS analysis might have a role to check
hether the pressures used have really fulfilled the job to
ptimally deploy the stent.
laque and vessel compliance. In IVUS studies, arterial
xpansion seemed to be the primary mechanism of lumen
nlargement after stenting, accounting for approximately
0% of luminal gain, whereas the relative contribution of
laque reduction ranged between 6% and 34% (47–49).
herefore, the presence of calcium or fibrosis that impairs
istensibility of the vessel wall and the presence of high
laque burden behind the stent might represent major
Role of IVUS-Guided Post-Dilation
Ultrasound Criteria of Optimal Stent Expansion
Rate of Patients
Fulfilling IVUS
Criteria After
Post-Dilation
Achievement of complete stent apposition to the
ssel wall;
Stent lumen CSA  the distal reference lumen CSA;
Absence of signiﬁcant lesion in nonstented adjacent inﬂow
d outﬂow segments
Not available
Intrastent CSA 80% of the average of the proximal and
stal reference lumen CSA
80%
MSA 90% of average reference lumen area by IVUS;
Absence of dissection;
Complete stent apposition
57%
ft to operator’s choice NA
Complete stent apposition;
In-stent minimal lumen area 90% of the average reference
men area or 100% of lumen area of the reference segment
ith the lowest lumen area;
Symmetric stent expansion deﬁned by LDmin/LDmax 0.7
50%
Complete stent apposition;
In-stent minimal lumen area 90% of the average reference
men area or 100% of lumen area of the reference segment
ith the lowest lumen area;
Symmetric stent expansion deﬁned by LDmin/LDmax 0.7
56%
Complete stent apposition;
In-stent MLD 80% of the mean of average vessel reference
ameter;
In-stent MLA greater than or equal to distal reference
men area
89%
ft to operator’s choice NA
rasound Influence Stent Expansion; CSA cross-sectional area; DS diameter stenosis; MACE
men diameter; MSAminimal stent area; NA not applicable; NS not significant; OPTICUS
its Outcomes; QCA  quantitative coronary angiography; RESIST  Restenosis after IVUS-guided
scularization; TULIP Thrombocyte activity evaluation and effects of Ultrasound guidance in Longg the
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26In this context, the negative influence of plaque burden
n adequacy of deployment has been demonstrated by Yoon
t al. (28) in a single center study on consecutive patients
ndergoing stent implantation with IVUS examination.
evertheless, in this study, the effect of stent post-dilation
as not been assessed. Similarly, calcified vessels affect final
tent lumen area, preventing complete expansion even when
igher pressures or larger balloons are applied (51). In this
ituation, the use of high-pressure balloon inflations deter-
ines vessel overexpansion at noncalcified segments rather
han compression of the calcific plaque. The net result is
hat a significant portion of stent remains underexpanded
nd asymmetric, which in turn probably explains the higher
ate of restenosis found in this type of lesion (39,52).
Therefore, in these situations, when ablative or atherec-
omy techniques are not feasible, the use of a noncompliant
alloon post-dilation represents a good compromise to
chieve good stent expansion and symmetry without in-
reasing risk of dissection or rupture of the vessel. In studies
n which IVUS analysis after post-dilation was accom-
lished, including the POSTIT (Postdilatation Clinical
omparative Study) trial (10), none of the baseline clinical
r angiographic variables seemed able to predict the final
SA or MSD after stenting. Similarly, neither quantitative
VUS lesion measurements nor qualitative IVUS assess-
ent of plaque morphology could predict stent expansion
18). These observations would suggest that the impact of
laque and vessel compliance on the final stent expansion
an be limited by an appropriate use of post-dilation.
esion characteristics. Specific lesion subsets are associated
ith a lower success rate and required more care and tools
o obtain an optimal stent deployment. Lesion subsets in
hich adequate post-dilation should be carefully considered
re summarized in Table 3.
IFURCATION LESIONS. Bifurcation treatment is associated with a
igh incidence of nonuniform stent expansion in the side
ranch, resulting in a higher TVR rate (53). Indeed, the
ateral opening of the stent in the main branch to gain access
o the side branch causes strut deformation and malappo-
ition (54–57). In this context, several studies showed that
n bifurcation lesions, especially in the case of both branches
tenting, final post-dilation with a kissing balloon is asso-
Table 3. List of Conditions Associated With an Increased Risk of
Suboptimal Stent Deployment
Low-pressure stent deployment (12 atm)
Lesions with heavy calciﬁcation
Lesions with large plaque burden (severe stenosis)
Lesions with a mismatch of proximal and distal reference size
Ostial lesions
Bifurcation lesions treated with stenting of side branch
Long lesions requiring multiple stent
Small vessel treatmentdTreatment of diffuse in-stent restenosisiated with more favorable long-term outcome, reducing the
estenosis rate of the side branch and the need for TLR
57–59). Thus, kissing balloon dilation at the end of the
rocedure is mandatory for bifurcations, but balloon diam-
ters and inflation pressures are yet to be defined to
niformly expand stent struts in both branches. In this
ontext, the use of adequately sized noncompliant balloons
t truly high pressures might represent a good compromise
etween safety and efficacy.
ONG LESIONS. Although lesion length does not influence stent
xpansion per se (44), the RENEWAL (Randomised Trial
f Endoluminal Reconstruction Comparing the NIR Stent
nd Wallstent in Angioplasty of Long Segment Coronary
isease) and MUSIC trials showed that the high restenosis
ates with long stents might be related to a suboptimal stent
eployment (2,60). Treatment of long lesions, especially
hen more than 1 stent is required or when long stents are
mplanted, increases the risk of size mismatch between the
roximal and distal portion of the target vessel. Indeed, in
uch cases, the stent is usually sized for distal reference
iameter and results undersized for the proximal reference
iameter. Furthermore, the presence of a double stent struts
ayer could reduce vessel compliance and can produce an
ncomplete stent apposition beneath the overlap. For these
easons, a systematic post-dilation of the proximal por-
ion of a long stent and of the overlapping zone with
igh-pressure inflations or a larger balloon is strongly
ecommended.
MALL VESSELS. In clinical practice, many interventional cardi-
logists generally avoid implantation of stents with a diam-
ter size smaller than 2.5 mm. Thus, for small vessels it is
ommon practice to deploy stents that are slightly larger but
t lower pressures to avoid excessive vessel overstretch. This
abit results in very high incidence of suboptimal stent
eployment and an increased incidence of TVR (20). As
reviously described, in this context it is fundamental to
ssess whether the vessel is really a small vessel or just
ppears as such at angiography. Nitroglycerine administra-
ion, IVUS evaluation, and bearing in mind that the left
nterior descending artery is rarely a small vessel unless in its
istal segment are important concepts. If the vessel’s small
ize were confirmed, post-dilation at higher pressures with a
.5-mm noncompliant balloon would represent an indis-
ensable solution to achieve the largest final lumen stent to
educe the risk of stent thrombosis and TVR.
N-STENT RESTENOSIS. Although DES use has also provided
ncouraging results in this setting, stent underexpansion is
he main predictor of in-stent restenosis, ranging between
0% and 40% of the cases (61–66). Interestingly, Blackman
t al. (67) showed that a noncompliant balloon post-dilation
s necessary during treatment of in-stent restenosis to
chieve luminal gain through further expansion of the
riginal stent, which cannot be obtained with a second stent
eployment alone. In this study, after post-dilation with a
n
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27oncompliant balloon, the number of patients with optimal
tent expansion according to the IVUS criteria increased
rom 33% to 67%. Thus, this study also demonstrated that,
ith post-dilation with noncompliant balloons, significant
tent re-expansion can be obtained during repeat angio-
lasty irrespective of the grade of initial stent underexpansion.
igh-Pressure Stent Deployment Versus
oncompliant Balloon Post-Dilation
everal studies (3,6) demonstrated that supranominal pres-
ures are frequently not enough to offset the high impedance
f diseased artery. In particular Bermejo et al. (6) showed
hat, despite high-pressure stent deployment, only 55% of
chievable acute lumen gain was effectively obtained, sug-
esting that plaque characteristics and vessel resistance often
ause inadequate expansion of semi-compliant balloons.
nfortunately, there is no guarantee that simple high-
ressure post-dilation with a noncompliant balloon will
esult in final optimal stent deployment.
Consequently, in the subsequent years, the use of IVUS
o optimize stent implantation became common practice,
nd several studies evaluated its role in PCI outcome. The
USIC study was the first large study that assessed the role
f IVUS-guided post-dilation to optimize stent deploy-
ent, demonstrating its favorable impact on immediate and
-month clinical and angiographic results (2).
Similarly, the POSTIT (10), CRUISE (7), and TULIP
8) studies clearly showed that systematic IVUS-guided
ost-dilation can provide a larger minimal stent area and
ow this might translate into better long-term outcome. In
articular, the multicenter POSTIT trial (10) showed that
djunctive a noncompliant balloon post-dilation can double
he frequency of achieving optimal stent deployment when
ompared with high delivery pressures. Furthermore, the
RUISE study demonstrated the clinical relevance of this
pproach, showing that an increase of 14% of the final MSA
btained in the IVUS-guided group resulted in a 44%
omposite relative reduction in TVR (7).
In contrast, other contemporary studies, such as the
ESIST (REStenosis after IVUS-guided STenting) (68),
PTICUS (Optimization with ICUS To Reduce Stent
estenosis) (69), SIPS (Strategy for Intracoronary ultrasound-
uided PTCA and Stenting) (70), and PRESTO (Prevention
f Restenosis with Tranilast and its Outcomes) (71) studies,
id not confirm the benefit derived from IVUS guidance for
ost-dilation on long-term results.
Although there is a trend toward a benefit in TLR
avoring IVUS-guided coronary stent implantation, espe-
ially in high-risk lesion subtypes (e.g., saphenous vein
rafts, long lesions), the effect on long-term death and
onfatal myocardial infarction is neutral (72).
The choice of more conservative IVUS criteria and theonsequent less aggressive stent post-dilation (Table 2), the seterogeneity with respect to the rate of patients fulfilling
he pre-specified IVUS criteria at the end of procedure, and
he underpowered design in most negative studies consti-
utes possible explanation of these conflicting results. Nev-
rtheless, apart from their specific characteristics and results,
ll of the studies cited in the preceding text undoubtedly
emonstrated that an adequate post-dilation is required to
ssure an optimal stent deployment in most of the lesions,
ndependently from the original pressure of stent deployment.
ompliant Versus Noncompliant
alloon Post-Dilation
or safety and deliverability reasons, most of the stent
elivery systems are currently based on a semi-compliant
alloon device. The compliant nature of these balloons
auses significant deformation of profile and volume with
ncreases in pressures, resulting in stretching of the balloon
tself. Thus, although current semi-compliant balloons are
recisely matched with stent length with very short balloon
houlders and assure a uniform diameter expansion along
he balloon length, the risk of vessel stretch and edges injury
s important at high pressures. Similarly, this technical
spect must be carefully considered during high-pressure
tent post-dilation with semi-compliant balloons.
Conversely, noncompliant balloons have little change in
olume, even at high pressures concentrating dilating force
t the lesion site (73). Indeed, bench tests and clinical
tudies have shown that noncompliant balloons exert more
ilating force against a lesion or a stent than compliant
alloons for a given balloon size and inflation pressure.
hus, post-dilation with noncompliant balloons actually
esults in a significant improvement of MSA compared with
he current semi-compliant stent deployment balloons.
specially, the use of a noncompliant balloon post-dilation
voids using a balloon larger than the reference vessel and
lso allows the application of very high pressures (just below
he rated burst pressure) in a safe manner. The main
ifference between compliant and noncompliant balloons
uring high-pressure inflation is shown in Figure 2.
These features can be important to prevent unwanted and
otentially severe complications caused by over-dilation or
ncontrolled fast stretch of the vessel wall. Using a compli-
nt balloon at high pressures, for example, in calcified or
ery stiff lesions might cause dissection at stent edges and, in
mall vessels, might facilitate coronary rupture. Several
nimal and human studies suggested that aggressive stent
nflation with high pressures, causing deeper injury of the
essel wall with rupture of the intima or media (74–76),
ight result in a long-term inflammatory response with a
reater neointimal proliferative response and an increased
estenosis rate (77,78). Moreover, a SIRIUS (SIRolImUS-
luting Stent in De Novo Native Coronary Lesions) IVUSubstudy (79) suggested that more injury to the contiguous
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28asoelastic normal wall, coupled with a drug that delays the
ealing process, could contribute to late stent malapposition
wing to focal positive vessel remodeling.
These considerations should lead to more common use of
noncompliant balloon for post-dilation at high pressure.
enefits of a Noncompliant Balloon Post-Dilation
fter DES Implantation
he main consequences of stent underexpansion are repre-
ented by higher rate of restenosis and related necessity of
epeated revascularization at long-term follow-up. More-
ver, with DES, potential increase in the risk of stent
hrombosis exists (80,81).
n-stent restenosis. Several studies demonstrated the impor-
ance of complete strut apposition, luminal CSA, and
oncentricity of the stent implanted (29,82). According to
hese data, IVUS measurement of MSA is the single most
owerful predictor of long-term patency and clinical out-
ome with an inverse relation between post-procedural
SA and angiographic restenosis and between MSA and
VR (4,37,38,40,83). In the TULIP study (8), for example,
estenosis rate was 23% in the group guided by IVUS versus
Figure 2. Difference Between Compliant and
Noncompliant Balloons During High-Pressure Inflation
Bench test showing the different proﬁle between a noncompliant balloon
(A) and a semi-compliant stent delivery balloon (B) during high-pressure
(14 atm) inﬂation. The semi-compliant balloon demonstrates a “dog
bone” effect at the edge of the cylinder that can damage the vessel wall
in vivo.5% in the angiography group, whereas the CRUISE trial w7) demonstrated a relative TVR reduction of 44% when
tent underexpansion was corrected by IVUS.
With the advent of DES, determining a lower rate of
ngiographic restenosis and clinical TVR, the need for
djunctive balloon post-dilation was considered less impor-
ant. Moreover, the possible role of vessel trauma at the
tent margins owing to pre- and post-dilation in determin-
ng sirolimus-eluting stent (SES) edge restenosis in the
IRIUS trial (14) led to a more extensive use of direct
tenting, whereas post-dilation was used only if strictly
equired by suboptimal angiographic stent placement (84).
n particular, a comparison study (85) between SIRIUS-US
pre- and post-dilation) and E-SIRIUS (direct stenting
nd nonmandatory post-dilation) IVUS results showed
hat, although the less aggressive stent implantation in
-SIRIUS resulted in a relatively lower stent expansion, no
etrimental effects were observed in major adverse cardiac
vents.
Subsequently, serial IVUS analyses from the SIRIUS trial
howed that, whereas a smaller MSA might be acceptable
fter DES, underexpansion can result in restenosis (21).
his finding was confirmed in other studies in which an
ncidence of 60% to 70% stent underexpansion determining
n MSA 5.0 mm2 was found in most of the cases of SES
ailures (86–88). Moreover, specific IVUS analysis of DES
ailure demonstrated a correlation between non-uniform
tent strut distribution and maximal neointimal hyperplasia,
uggesting local drug underdosing as mainly responsible for
his phenomenon (16,89).
In conclusion, observational data suggest that stent un-
erexpansion might be one of the most important causes of
ES failure, advocating that, once neointimal hyperplasia is
uppressed, the optimum stent deployment is still funda-
ental. Therefore, post-dilation with noncompliant bal-
oons at high pressures, improving final MSA and MSD,
ight greatly increase the frequency of optimum DES
eployment and actually lead to reduction of restenosis and
VR rates. To specifically address the exact role of high-
ressure noncompliant post-dilation strategy, randomized
linical studies are warranted in the DES era.
tent thrombosis. Stent thrombosis remains a potential
evastating complication in patients undergoing PCI. In the
urrent era of high-pressure stent implantation, the occur-
ence of stent thrombosis with BMS ranges from 1% to 2%
36,90). Conversely, the rate of DES thrombosis ranges
etween 0.4% to 0.6% (14,15) of the randomized trials and
.3% to 4.9% of “real world” registries (24,80).
The major post-procedural predictors of thrombosis with
oth BMS and DES are MSA and suboptimal stent
xpansion (23,36,91); in particular, stent underexpansion,
esulting in abnormal shear stress, might explain as much as
0% of those events (22,92).
In a large registry of 7,484 consecutive patients treatedith BMS, only 22% of patients that experienced subacute
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29tent thrombosis had an optimum PCI result as assessed by
VUS. In this study, the IVUS analyses of thrombosed
tents revealed an inadequate lumen dilation (final lumen
80% reference lumen) in 78% of cases, edge dissection in
7%, malapposition in 9%, and plaque prolapse in 4% (92).
The importance of complete stent expansion to prevent
tent thrombosis might be more relevant with DES. Indeed,
ecreased endothelialization associated with drug-related
nhibition of neointimal proliferation might increase the
isk of stent thrombosis in the case of suboptimal stent
xpansion. Fujii et al. (23) showed in a retrospective study
hat lesions leading to stent thrombosis after successful SES
mplantation more often have stent underexpansion, smaller
SA, and residual edge stenosis. This evidence has also
een confirmed for the late-thrombosis cases of DES (12
onths) (91), but in this case, the pathophysiology mech-
nism is likely more complex (e.g., late acquired incomplete
tent apposition) and not completely understood (93).
In this view, the less care used by operators to obtain an
ptimal stent deployment and a lower use of post-dilation
ight represent a possible explanation of the higher rates of
tent thrombosis observed with DES. Thus, in absence of
onclusive data regarding DES long-term safety, it is
easonable to hypothesize that a return to the “antique”
ractice of a noncompliant balloon post-dilation could also
esult in an overall reduction of the risk of stent thrombosis
ith DES.
onclusions
n clinical practice, according to the rate of suboptimal stent
eployment reported in different studies, a considerable
umber of patients might benefit from repeat inflations with
oncompliant balloons at higher pressures and/or with
arger diameter size. Indeed, although incomplete stent
xpansion was attributed as a defect of the first-generation
alloon-expandable stent, several studies demonstrated that
djunctive balloon dilation is still necessary to improve the
inimum stent area and the volumetric expansion through-
ut the stented segment.
Data from the literature suggest that achieving adequate
tent expansion during PCI is important to reduce resteno-
is and the need for TVR, but it might also minimize the
isk of stent thrombosis in the DES era. Although there are
ot enough randomized data to support its use, it seems
ise to perform post-dilation with noncompliant balloons at
igh pressures in the majority of patients undergoing both
MS and DES implantation. Particularly in IVUS-guided
rocedures, the recommended strategy to achieve an opti-
al stent deployment should be to select a noncompliant
alloon whose size matches the media-to-media IVUS
easurement.
Unfortunately, it is not practical and cost-effective toerform post-dilation in all patients undergoing stent im-lantation. A more reasonable approach would then be to
elect those situations in which the risk of suboptimal stent
elivery is higher, especially when DES are employed.
Randomized controlled trials to assess the role of IVUS-
uided optimal stent implantation with DES are warranted.
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